Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Haemostatix logo — Bringing innovative solutions to manage and treat bleeding d...

Haemostatix

Bringing innovative solutions to manage and treat bleeding during surgeries, trauma cases, and leukemia treatment with advanced peptide-based technology.

Founded 2003 Venture round Total: $4.06M Biotechnology, Health Care

General Information

Company Name Haemostatix
Founded Year 2003
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Haemostatix. To contact Haemostatix, visit haemostatix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Haemostatix compare?

A PDF of Haemostatix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Haemostatix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Haemostatix

Haemostatix is a biotechnology startup based in Nottingham, UK, co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The company aims to revolutionize bleeding management during surgeries, trauma cases, and leukemia treatment with its advanced peptide-based technology. Haemostatix has developed a unique peptide sequence that binds to fibrinogen, a crucial protein for clot formation, and combines it with various solid supports or soluble carriers to create both topical and systemic haemostats. The company's innovative technology platform underpins a pipeline of first-in-class products dedicated to treating various types of bleeding in surgical procedures, trauma situations, and for leukaemic patients. In November 2014, Haemostatix secured a £61.61K Venture Round investment from Albion Capital. With its focus on biotechnology and healthcare, Haemostatix is well-positioned to make a significant impact in the field of bleeding management, and its innovative approach has garnered the attention of investors looking to support groundbreaking solutions in the healthcare industry.

Business keywords: BioCity, Nottingham, Haemostatix Ltd, surgical procedures, trauma treatment, leukemia treatment, peptide-based technology, clot formation, fibrinogen, commercialization, technology platform, spin-out, University of Leicester, first-in-class products, bleeding management

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round £61.61K 1
Albion Capital
Albion Capital
11 Nov 2014
Venture Round £100.00K 1
Albion Capital
Albion Capital
05 Mar 2014
Venture Round £2.20M 6
Albion Capital Nesta Ventures Spark Ventures
Albion Capital, Nesta Ventures +4
02 Nov 2012
Series C Undisclosed 4
Nesta Ventures Spark Ventures Catapult Venture Managers
Nesta Ventures, Spark Ventures +2
01 Aug 2011
Venture Round £459.00K 4
Nesta Ventures Spark Ventures Wellcome Trust
Nesta Ventures, Spark Ventures +2
11 Nov 2010
Venture Round £1.24M 3
Nesta Ventures Spark Ventures Catapult Venture Managers
Nesta Ventures, Spark Ventures +1
24 Apr 2008
Venture Round Undisclosed 1
Spark Ventures
Spark Ventures
01 Jan 2005

Haemostatix Alternatives & Competitors

View All Alternatives
Haemostatix vs
Rambam Health Care Campus
Rambam Health Care Campus Israel

Northern Israel’s largest hospital, and both the landmark and standard of quality for healthcare in...

1831 employees
Biotechnology, Health Care
Haemostatix vs
Biocomposites
Biocomposites United Kingdom

We engineer, manufacture and market world leading products for use in infection management in bone a...

Private Equity
296 employees
Biotechnology, Health Care
Haemostatix vs
Akebia Therapeutics
Akebia Therapeutics United States

We're focused on the development & commercialization of therapeutics for people living with kidney d...

Post-IPO Debt
268 employees
Biotechnology, Health Care
View all alternatives

FAQ About Haemostatix

Bringing innovative solutions to manage and treat bleeding during surgeries, trauma cases, and leukemia treatment with advanced peptide-based technology.
Haemostatix was founded in 2003.
Haemostatix operates in Biotechnology and Health Care. Its work centres on BioCity, Nottingham, Haemostatix Ltd and surgical procedures.
Haemostatix has completed 7 funding rounds, raising a total of $4.06M. The latest funding stage is Venture round.
Top alternatives and competitors to Haemostatix include Rambam Health Care Campus, Biocomposites, Akebia Therapeutics, Clover Biopharmaceuticals, Paladin Labs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Haemostatix and Rambam Health Care Campus are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Haemostatix, https://bouncewatch.com/company/haemostatix, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes